Introduction to Cannabis-Based Pain Relief
An experimental medication made from marijuana successfully reduced back pain in a new study, offering further support for the drug’s potential in treating one of the most common forms of chronic pain. The 800-patient study by a German drugmaker is the latest evidence of the therapeutic properties of cannabis, which remains illegal under U.S. federal law even as most states have made it available for medical or recreational use.
Background on Cannabis Approval
Health officials in Canada and Europe have previously approved a pharmaceutical-grade form of cannabis for several types of pain, including nerve pain due to multiple sclerosis. In the U.S., the Food and Drug Administration has approved a drug containing CBD — one of the many non-intoxicating chemicals found in cannabis — to treat rare seizures in children with epilepsy.
The New Cannabis Formula
Unlike that drug, known as Epidiolex, the new cannabis formula from drugmaker Vertanical contains THC, the active ingredient in marijuana that gets users high. But levels of the chemical are very low, essentially a microdose compared to what’s available in gummies, chocolate bars and other products sold at marijuana dispensaries in the U.S. The company said patients in the trial didn’t show any signs of drug abuse, dependence or withdrawal.
By MATTHEW PERRONE, AP Health Writer
Target Patient Group
Vertanical is seeking approval for a large group of patients: those suffering from lower-back pain, a chronic condition that affects millions and has few proven treatments. Over-the-counter pain relievers like ibuprofen can’t be used for long-term pain because of their side effects, which include stomach ulcers and indigestion. Opioids are no longer recommended, after the overprescribing of painkillers such as OxyContin in the 1990s and 2000s led to the ongoing epidemic of addiction to that class of drug.
Study Details and Findings
Chronic pain is one of the most frequently cited conditions of people enrolled in state-run medical marijuana programs. But there’s been little rigorous research on the drug’s use in that group. Lead study author Dr. Matthias Karst said in an email that the new findings show cannabis “can significantly reduce pain and improve physical function in patients with chronic low-back pain, without the safety concerns commonly associated with opioids.” Karst is a pain specialist at Hannover Medical School and a consultant for Vertanical. For the new study, patients with back pain were randomly assigned to take Vertanical’s proprietary liquid cannabis extract or a placebo. At the end of 12 weeks, patients taking the medication reported a nearly 2-point reduction in pain on an 11-point scale, compared with 1.4 points for those taking placebo. The difference was statistically significant. Those getting the drug also reported improvements in sleep and physical function.
Long-Term Effects and Side Effects
Patients who continued with a six-month extension phase continued to experience reductions in pain. The results were published Monday in the journal Nature. Side effects included dizziness, headache, fatigue and nausea and led to more than 17% of people discontinuing the drug early. Researchers said that dropout rate was lower than what’s typically reported with opioids, which can cause constipation, nausea, drowsiness and carry risks of addiction.
Regulatory Approval and Future Plans
Vertanical has filed an application for its drug with European regulators. In the U.S., the company says it is “working closely” with regulators to design a study to support FDA approval. The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. Originally Published: September 29, 2025 at 11:59 AM EDT
Conclusion
The study’s findings offer new hope for individuals suffering from chronic lower-back pain, a condition that has limited treatment options. The success of Vertanical’s cannabis-based medication in reducing pain and improving physical function without the risks associated with opioids is a significant step forward. As the company seeks regulatory approval, it’s essential to continue monitoring the drug’s effects and side effects to ensure its safety and efficacy for long-term use.
FAQs
- Q: What is the new cannabis formula made by Vertanical, and how does it differ from existing cannabis products?
A: The new formula contains THC, the active ingredient in marijuana, but at very low levels, essentially a microdose. This distinguishes it from products available at marijuana dispensaries and other pharmaceutical-grade cannabis products. - Q: What were the findings of the 800-patient study on the use of cannabis for lower-back pain?
A: Patients taking the medication reported a nearly 2-point reduction in pain on an 11-point scale, compared with 1.4 points for those taking a placebo, with statistically significant differences. Improvements in sleep and physical function were also reported. - Q: What are the next steps for Vertanical in terms of regulatory approval?
A: Vertanical has filed an application with European regulators and is working closely with U.S. regulators to design a study that will support FDA approval.
